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Abstract
OBJECTIVES—Recent experimental evidence suggests that environmental microbial factors
early in life determine susceptibility to allergic diseases through inappropriate chemotaxis and
local activation of CD1d-restricted, invariant chain natural killer T (iNKT) cells. In this study, we
analyzed the involvement of these pathways in pediatric patients with eosinophilic esophagitis
(EoE) before and after dietary allergen elimination.
METHODS—mRNA expression levels of components of the C-X-C motif chemokine ligand 16
(CXCL16)–iNKT–CD1d axis were compared in esophageal biopsies from EoE patients vs. normal
or inflammatory controls and before and after treatment.
RESULTS—CXCL16, iNKT cell–associated cell marker Vα24, and CD1d were significantly
upregulated in esophageal biopsies from EoE patients and correlated with the expression of
inflammatory mediators associated with allergy. Upregulation of each of these factors was
significantly more pronounced in patients aged < 6 years at diagnosis, and this early-onset EoE
subpopulation was characterized by a more prominent food allergic disease phenotype in a cohort-
wide analysis. Successful, but not unsuccessful, treatment of early-onset EoE patients with dietary
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elimination of instigating allergens led to reduction in infiltrating iNKT cells and complete
normalization of mRNA expression levels of CXCL16 and CD1d.
CONCLUSIONS—Our observations place iNKT cells at the center of allergic inflammation
associated with EoE, which could have profound implications for our understanding, treatment
and prevention of this and other human allergic diseases.
INTRODUCTION
A wide variety of allergic and immune-mediated inflammatory disorders are rapidly and
globally increasing (1,2), suggesting that environmental factors are critical mediators of
these changes (3). Moreover, the increasing incidence of these diseases is especially
apparent among children (4–6), which implicates a role for the environment in the processes
of education and development of the immune system that follow the acquisition of a
commensal microbiota along mucosal surfaces early in life (7,8).
Recently, direct evidence has emerged from animal models of asthma and inflammatory
bowel disease (IBD) that microbially derived signals during a critical neonatal time frame
are important regulators of later-life susceptibility to immune-mediated diseases (9).
Furthermore, environmentally induced disruptions of these signals, such as those that result
from the use of antibiotics, conferred increased susceptibility to experimental asthma and
IBD (9,10). These rodent models have focused particular attention on the role played by
microbial-induced expression of chemoattractant chemokines that promote infiltration of
mucosal tissues with invariant natural killer T (iNKT) cells. iNKT cells respond to host and
microbial lipid antigens when presented by CD1d and rapidly express a variety of mediators
that regulate downstream immune events and effector cells (11,12). In the absence of
microbiota during neonatal, but not adult life, as in germ-free or antibiotic-treated mice,
such tissues express increased quantities of C-X-C motif chemokine ligand 16 (CXCL16), a
chemokine involved in iNKT cell trafficking (9,13). When these early-life microbial signals
are not provided, an excessive and persistent accumulation of iNKT cells occurs in the colon
and lungs. Consequently, these mucosal tissues are rendered more susceptible to later-life
environmental triggers of iNKT cells, which are potent and rapid producers of T helper type
2 (Th2)-type cytokines such as interleukin (IL)-4, IL-5, and IL-13, which mediate allergic
sensitization and tissue inflammation (9,12,14). These model studies suggest that
microbially regulated immune events during early life, or lack thereof as a consequence of,
for example, antibiotic administration, are critical determinants of later-life susceptibility to
allergic disease. In addition, given that components of CD1d-restricted T-cell pathways and
their regulating factors such as CXCL16 serve as mediators of this susceptibility, it is
reasonable to expect that they have a potential role as markers for disease risk in humans.
To test the relevance of the hypothesis that early-life events determine the tone of CD1d-
restricted T-cell pathways and susceptibility to immune-mediated diseases in humans, we
turned our attention to pediatric patients with eosinophilic esophagitis (EoE). EoE is
characterized by chronic eosinophilic inflammation of the esophagus and is strongly
associated with allergies to inhaled and food-derived antigens (15,16). Like other allergic
diseases, the disorder often manifests during childhood (17) and is undergoing a rapid
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increase in incidence and prevalence worldwide (6,18,19), suggesting a pathogenic role of
yet-to-be defined environmental factors (16).
In addition to their previously established role in asthma and IBD (20,21), iNKT cells have
recently been implicated in the pathogenesis of experimental EoE (22). To study the
involvement of this pathway in EoE, here we analyzed the mRNA expression levels of
CXCL16, as well as iNKT cells and their markers, in serum and esophageal biopsies that
were obtained before and after treatment with an allergen-elimination diet.
METHODS
Study population
The patients included in this study are part of an observational longitudinal cohort study at
Boston Children’s Hospital that aims at understanding the pathophysiology of EoE and is
approved by the institutional Investigational Review Board (Harvard Medical School,
Boston, MA) (23–25). Parents of children aged 0–18 years whose clinical presentation
indicated possible EoE (e.g., feeding intolerance, food aversion, dysphagia, failure to thrive)
were invited to participate. Before routine diagnostic endoscopy, caregivers were asked to
fill out a questionnaire regarding the child’s past medical history, current and past
symptomatology, allergic comorbidity, and dietary habits. We only considered children to
be food allergic when foods were avoided based on the results of RAST (radioallergosorbent
test), skin prick, or patch testing. Upon written informed consent, serum and additional
esophageal biopsies were obtained. EoE was diagnosed according to the current consensus
guidelines (26). After diagnosis, patients were treated independently of this study but were
again asked to participate when admitted for follow-up endoscopy. Since 2008, 451 children
have been included in the cohort, 160 of whom received a diagnosis of EoE. The 291 non-
EoE patients had either normal esophageal tissue biopsies (N = 225) or inflammation that
was classified by the hospital pathologist as consistent with reflux esophagitis (N = 66).
Within this patient cohort, we focused on 31 biopsies available from patients aged < 6 years
(18 EoE, 5 reflux esophagitis, and 8 normal histology) as well as 16 biopsies from patients
aged ≥6 years old (10 EoE, 6 normal histology). Twelve follow-up biopsies from EoE
patients aged < 6 years were available for analysis.
Sample preparation and assay
Study biopsies from the distal esophagus (approximately 2 cm from the gastro-esophageal
junction) were collected in RNA later (Qiagen, Valencia, CA) and stored at −80 °C before
processing. Tissue was homogenized in 350μl RLT Buffer (Qiagen) with β-mercaptoethanol
(Sigma, St Louis, MO) in GentleMACS M tubes (Miltenyi Biotec, Auburn, CA), and RNA
was extracted using the RNeasy plus kit (Qiagen). RT-qPCR (quantitative reverse
transcriptase–PCR) was performed using Taqman gene expression assays (Applied
Biosystems, Foster City, CA) for CXCL16, CD1d, CD1a, C-X-C motif chemokine receptor
6 (CXCR6), TRAV10 (Vα24), CD3ε, leukotriene C4 synthase (LTC4S), eotaxin-3, and
periostin in duplex RT-qPCR reactions with the housekeeping gene GAPDH
(glyceraldehyde 3-phosphate dehydrogenase; C1000 Thermal Cycler, Bio-Rad, Herculus,
CA). Gene expression relative to GAPDH (ΔΔ) was calculated. Pooled cDNA from five
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control patients was used as an inter-run calibrator. CXCL16 protein levels were measured
in serum using a commercially available enzyme-linked immunosorbent assay according to
the manufacturer’s instructions (R & D Systems, Minneapolis, MN).
Statistical analysis
Distribution of serum and mRNA expression values was assessed with D’Agostino and
Pearson omnibus normality test and patient groups were accordingly compared with either
Student’s t-test for normally distributed or Mann–Whitney U test for non-parametric values
unless otherwise indicated. Correlations were expressed as Pearson’s or Spearman’s ρ.
Epidemiological data retrieved from questionnaires was analyzed with Fisher’s exact test.
For logistic regression analysis, potential predictors of EoE that were estimated to relate
directly to the report of early-life antibiotic use were analyzed with univariate logistic
regression and subsequently included in a multivariate model, regardless of statistical
significance. Analyses were performed with Stata 12.1 (StataCorp, College Station, TX) and
Prism 5.0 (GraphPad Software, La Jolla, CA). Reported values represent mean ± s.e.m. All
statistical testing was two-sided, with an α of 0.05.
RESULTS
The CXCL16–iNKT–CD1d axis is prominently involved in early-onset EoE patients
To investigate the contribution of CXCL16 to local disease in EoE, we analyzed mRNA
expression levels of CXCL16 in esophageal biopsies at the time of diagnosis in 47 children.
Patients were grouped according to age at diagnosis: (i) patients aged < 6 years (18 EoE vs.
13 non-EoE, of whom 5 with histological evidence of reflux esophagitis) and (ii) 6–18 years
(10 EoE vs. 6 non-EoE with normal tissue histology). CXCL16 was expressed in all
esophageal biopsies analyzed (cycle threshold range 26.6–32.7), but expression was
significantly higher in EoE patients when compared with controls (3.2 ± 0.3 vs. 1.2 ± 0.2, P
< 0.001, Figure 1a). Furthermore, expression levels were higher in early-onset EoE patients,
which we defined as children diagnosed < 6 years of age, compared with their older EoE
counterparts (3.7 ± 0.4 vs. 2.2 ± 0.2, P < 0.05). No age-dependent difference was seen in the
non-EoE control patients (1.3 ± 0.3 vs. 1.0 ± 0.1, P = 0.52, Figure 1a).
We analyzed the same biopsies for mRNA expression of CXCR6, the canonical receptor for
CXCL16 that is expressed on a variety of T-cell subsets, including Th1-polarized CD4+ and
CD8+ T cells (27), as well as iNKT cells (28). Although higher expression levels were seen
in EoE patients compared with non-EoE controls (Figure 1b), the highest expression levels
were observed in EoE patients aged 6–18 years. In light of the elevated CXCL16 levels
observed in EoE patients < 6 years old, these results are consistent with observations that
CXCR6 in T cells is downregulated upon activation (29) and suggest that CXCL16
engagement is highly active in early-onset EoE patients.
To determine whether CXCL16 overexpression was indeed associated with infiltration of
iNKT cells, we analyzed gene expression of Vα24, an essential component of the invariant
T-cell antigen receptor (TCR) of iNKT cells (30). Vα24 TCR mRNA transcripts were
detected in 17 of the 18 early-onset EoE patients, all 10 older EoE patients, and in 14 of the
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19 control patients. In line with CXCL16 expression results, the highest levels of Vα24 TCR
mRNA were detected in EoE patients aged < 6 years (Figure 1c). Increased Vα24
expression did not result from more pronounced overall T-cell infiltration, because
expression levels of the ε chain of the TCR (CD3ε) were equivalent in both young and older
EoE patients (Figure 1d), and normalization of Vα24 expression against CD3εor CXCR6
did not resolve the difference between old and young EoE patients (Figure 1e). These results
suggest the existence of distinct differences in infiltrating T-cell subsets between early-onset
and older EoE patients.
iNKT cells are restricted by recognition of lipid antigen presented through CD1d on antigen-
presenting cells (12). We therefore examined CD1d mRNA and observed increased
expression in EoE patients compared with non-EoE control patients, indicating that at the
site of inflammation there is an enhanced capacity to activate infiltrating iNKT cells (Figure
1f). Indeed, we depicted a positive correlation between tissue mRNA expression of CD1d
and Vα24 in esophageal biopsies (Spearman ρ = 0.654, P < 0.001, Figure 1g). Similarly,
expression of CXCL16 and Vα24 correlated positively (Spearman ρ = 0.542, P < 0.001,
Figure 1g). Conversely, expression levels of CD1a, a related glycoprotein on antigen-
presenting cells, did not differ between EoE patients and controls (1.0 ± 0.2 vs. 1.2 ± 0.2, P
= 0.38), arguing that increased CD1d expression in EoE is part of the disease-specific
immune phenotype rather than the result of overall increase in tissue myeloid or
inflammatory cells (Figure 1h). Combined, these data show local involvement of the
CXCL16–iNKT–CD1d axis in EoE patients and that this involvement is significantly more
prominent in early-onset EoE patients.
Serum CXCL16 levels in early-onset EoE patients are consistent with an age-dependent
role in EoE pathogenesis
CXCL16 is present as a membrane-bound protein on epithelial and myeloid cells, as well as
a soluble form, that can be retrieved from patient serum (31). We hypothesized that early-
onset EoE patients might also be characterized by higher levels of CXCL16 in serum when
compared with non-EoE control patients, as was observed in tissues (Figure 1a). If so, this
might serve as a convenient biomarker for disease. Serum levels were similar between the
patient groups (2.9 ± 0.2 μg / ml for EoE (N = 18) vs. 2.6 ± 0.1 μg/ml for non-EoE (N = 24),
P = 0.19, Figure 1i). Interestingly, there was a significant negative correlation between
serum CXCL16 levels and age of diagnosis in EoE (r = −0.65, P = 0.004, Figure 1j).
Conversely, this relationship between age and serum CXCL16 levels was absent in the non-
EoE patients (r = −0.16, P = 0.46, Figure 1j) and EoE patients aged 6–18 years (N = 8, r =
0.31, P = 0.45). These results further support an age-dependent role for CXCL16 in EoE
pathophysiology, which is detectable in the serum.
Involvement of the CXCL16–iNKT–CD1d axis is associated with a more pronounced food
allergic phenotype
As CXCL16 overexpression and iNKT cell infiltration were significantly more pronounced
in the younger EoE patients, we asked whether early-onset EoE differs from EoE that
becomes apparent during later childhood. Within our entire cohort of 451 patients, 44 of the
160 EoE patients (28 %) were < 6 years at the time of diagnosis. In line with data from
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multiple patient populations (6,19), we saw a strong male preponderance in EoE patients, as
well as a higher occurrence of all investigated allergic diatheses compared with control
patients (Table 1). Comparison between EoE patients aged < 6 and ≥6 years, however,
revealed striking differences in the distribution of allergic comorbidity. Whereas older
patients were more likely to be asthmatic (50 vs. 20 %, P = 0.003), early-onset EoE patients
had significantly more often been diagnosed with food allergy against milk (32 vs. 14 %, P
= 0.02) or any specific food allergen (48 vs. 25 %, P = 0.008) through skin prick, patch, or
RAST testing. These epidemiological data are suggestive of a particularly dominant role of
food allergic sensitization in early-onset EoE.
To further test this hypothesis at the tissue level, we again turned to tissue biopsies. We have
recently demonstrated that elevated mRNA levels of LTC4S mark a subpopulation of EoE
patients with a more pronounced local allergic phenotype (25). No difference was found in
tissue eosinophil counts between early and later-onset EoE patients (Figure 2a). However, in
line with our epidemiological data, we found that early-onset EoE patients had significantly
higher levels of LTC4S mRNA expression (Figure 2b).
In addition, we analyzed tissue biopsies for EoE marker genes eotaxin-3, periostin, and
IL-13, which were among the first genes to be identified as part of an EoE-specific
esophageal transcriptome (32–34). We observed that all were increased in patients with EoE
relative to the non-EoE subjects (Figures 3c–e). Although no age-dependent differences in
expression were found, we observed a strongly positive correlation between tissue mRNA
expression levels of CXCL16 and these marker genes (Figure 3c–e). Eotaxin-3 has been
identified as one of the key eosinophil attractant cytokines in EoE (32), and periostin is
described to facilitate eosinophil tissue infiltration (33). Expression of both effector
molecules has been described to occur downstream of IL-13 signaling in EoE (33,34).
Although IL-13 is produced by iNKT cells (12), we did not observe a significant correlation
between expression of IL-13 and Vα24 (r = 0.13, P = 0.50), indicating that iNKT cells are
unlikely to be the dominant cellular source of IL-13. These data suggest a link between the
local expression of CXCL16 and effector pathways of EoE at the site of tissue inflammation.
Treatment with elimination diet leads to normalization of the CXCL16–iNKT–CD1d axis in
early-onset EoE patients
To analyze the response of the CXCL16–iNKT–CD1d axis to EoE treatment, we repeated
mRNA measurements in biopsies that were obtained during follow-up endoscopies
performed to monitor disease progression and therapeutic response. Follow-up biopsies were
available from 12 of the 18 early-onset EoE patients after a median follow-up time of 10.1
months (range 1.9–24.8 months). Based on the degree of tissue eosinophilia obtained from
routine histopathological analysis, 7 of the 12 EoE patients had significantly improved with
treatment, with median eosinophil counts of 8 / high power field (hpf) (range 0–25)
compared with the initial biopsies that showed a median of 100 eosinophils / hpf (range 37–
120, P = 0.02 by Wilcoxon signed rank test, Figure 3a). Conversely, in the five non-
responding patients, tissue eosinophilia at follow-up remained high, ranging from 40 to 120
eosinophils / hpf (median 100 / hpf, P = 0.25). In line with tissue eosinophil counts and
previously published data (34), mRNA expression levels of eotaxin-3 and periostin at
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follow-up had decreased significantly in responding patients, whereas this reduction was
smaller and not significant in the non-responders (Figure 3a). Patient and treatment details
are summarized in Table 2.
We next turned our attention to the CXCL16–iNKT cell–CD1d axis in treated patients. We
observed that, in the seven responders, CXCL16 mRNA expression completely normalized
to the expression levels encountered in age-matched control patients (1.2 ± 0.1 vs. 1.3 ± 0.3,
P = 0.88, Figure 3b). In contrast, CXCL16 expression remained significantly elevated in the
five non-responders (2.3 ± 0.4) when compared with control patients (P = 0.01) as well as
responding EoE patients (P = 0.03). CXCR6 and Vα24 TCR mRNA levels also decreased
significantly in the seven responding patients (2.7-fold, P = 0.02 and 3.3-fold, P = 0.03,
respectively) but not in the non-responders (P = 1.0 and P = 0.63, Figure 3c). Likewise,
response to treatment was associated with a 17-fold reduction in CD1d expression (P = 0.01)
compared with a 1.5-fold reduction in non-responders (P = 0.31, Figure 3d). No decrease,
but rather an increase, in CD1a expression levels was observed upon successful treatment
(2.0-fold increase, P = 0.03), in this case showing that reduction of CD1d mRNA levels did
not result from decreased myeloid cell infiltration (Figure 3e). Finally, we found that LTC4S
mRNA levels only decreased following successful treatment (4.0-fold, P = 0.03 compared
with 1.3-fold, P = 0.81 in non-responders, Figure 3f). Allergen avoidance therapy did not
affect the levels of serum CXCL16 (Figure 3g), confirming that upregulation of CXCL16
represents a local mucosal event that is not broadcasted systemically. Together, these data
show that involvement of the CXCL16–iNKT cell–CD1d axis can be modified by dietary
interventions that aim to eliminate common allergens from the diet.
EoE is potentially associated with use of antibiotics during the first year of life
Animal model experiments suggest that CXCL16 overexpression by epithelial cells can
result from inadequate instruction from the commensal microbiota at an early age (9). We
therefore hypothesized that antibiotic treatment during the first year of life may be
associated with the development of EoE, as has been previously suggested for pediatric IBD
(35) and asthma (36) and, very recently, also for EoE (37). Unfortunately, our questionnaires
at the time of study enrollment did not directly address the extent of early-life antibiotic
exposure or mode of delivery but instead inquired into medication use during the first year
of life, in particular the use of antacids, corticosteroids, and prokinetics. Data on the
prescription of antibiotics was obtained through an open-ended question asking parents to
list additional medications during the first year of life. Questionnaires of 451 patients (160
EoE) were analyzed. Antibiotics in the first year of life were reported in 29 patients, of
whom 20 were subsequently diagnosed with EoE (P < 0.001). Although it is very likely that
under-reporting affected the total number of cases, the difference between EoE patients and
controls is unlikely the result of recall bias. This is because report of non-antibiotic drug-use
during the first year of life did not differ between cohorts (33 % of EoE patients vs. 41 % of
non-EoE controls, P = 0.09), and questionnaires were filled out before diagnosis.
Furthermore, a positive association (odds ratio 4.10, 95 % confidence interval 1.36–12.35)
between EoE and reported antibiotics use during the first year of life remained after
adjustment for sex, age, prematurity, hospitalization in the first year of life, allergic
comorbidities, and non-antibiotic drug use in the first year of life (Table 3). Although
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statistical significance was reached for this association in our cohort, additional
epidemiological studies designed to specifically address this question are needed to confirm
a causative link between early-life antibiotic exposure and occurrence of EoE later in life.
DISCUSSION
In the current study, we provide evidence that supports the involvement of CD1d-restricted
iNKT cell pathways in the pathogenesis of pediatric EoE. There are several key elements
associated with the findings contained here. First, our results provide a direct human
corollary of previous observations in animal models that commensal microbes, in an age-
dependent fashion, regulate iNKT cell accumulation in the colon and lung by altering
expression of chemokine ligands that promote iNKT cell migration, such as CXCL16.
Similar to this previous report, we found that all of the factors associated with iNKT cells
such as the associated TCR chain (Vα24), the antigen-presenting molecule that regulates
their activity (CD1d), and the chemokine ligand that determines their chemotaxis into tissues
(CXCL16), are observed at significantly higher levels in the esophageal tissue of EoE
patients compared with normal or inflammatory controls. Moreover, the highest levels were
observed in children with early-onset EoE (< 6 years), and the elements of the CXCL16–
iNKT cell–CD1d pathway correlated with the presence of inflammatory mediators
associated with EoE-specific inflammation (eotaxin, periostin), pointing towards a direct
role in disease pathogenesis. Indeed, successful dietary therapy was associated with the
resolution of disease, together with a synchronous and proportionate decrease in the levels
of CXCL16, CD1d, and Vα24, suggestive of a cause-and-effect relationship. Given the
observations in animal models, these findings in humans with EoE support the hypothesis
that early-life events that affect CD1d-restricted T-cell pathways at mucosal surfaces have
an important role in the pathogenesis of EoE. Indeed, we detected an association between
antibiotic use in the first year of life and the development of EoE, drawing additional and
provocative similarities to the aforementioned animal studies. Together, these studies
support the concept that a pathway involving environmentally induced changes in early life,
in this case caused by antibiotic administration, cause perturbations in mucosal iNKT cell
homeostasis in esophageal tissues and determines susceptibility to EoE.
Previous translational studies on the role of iNKT cells in human allergy have
predominantly been performed in asthmatic patients, after it was shown that iNKT cells are
required for the induction of experimental airway hyper-reactivity in mice (12,38,39). As
efforts to demonstrate increased levels of iNKT cells in bronchoalveolar lavage fluid of
asthmatic patients have not yielded clear differences with control populations (30,40,41),
such a role has remained a matter of debate (21,42). These analyses of bronchoalveolar
lavage fluid have, however, been performed in adult patients with a longstanding history of
asthma and therefore do not rule out a potential role for iNKT cells in the early phase of
disease pathogenesis. This concept is further supported by recent experimental work that
suggests that rather than being the main effector cell in advanced asthma, iNKT cells are
critically involved in the allergic sensitization phase of disease. Specifically, Scanlon et al.
(14) showed that intratracheal exposure to bacterial lipid antigens resulted in rapid
peribronchiolar infiltration of iNKT cells and formation of eosinophil- rich granulomas.
Upon intratracheal co-administration of ovalbumin, a Th2 immune response was mounted
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against ovalbumin, including synthesis of anti-ovalbumin immunoglobulin E. Allergic
sensitization persisted until months after the initial exposure and, once established, was
independent of iNKT cells (14). These observations thus point towards iNKT cells as a
crucial instigating cell type in allergic forms of inflammation and demonstrate that once
allergic sensitization has occurred, cytokine production by iNKT cells is dispensable for
disease pathogenesis. The latter finding likely explains the absence of a correlation between
IL-13 and Vα24 expression in our cohort.
By studying pediatric EoE patients at the time of diagnosis, we were able to obtain affected
mucosal tissues to directly correlate the involvement of iNKT cells and their mediators with
disease phenotype. Like asthma, EoE is a chronic, immune/antigen-driven condition
characterized by aberrant Th2 immune responses and allergic sensitization (26). Both food-
derived and inhaled allergens have been implicated in its pathogenesis (26,43,44), which is
reflected in high response rates upon initiation of an elemental or six-food elimination diet
(45,46). As a corollary, increased esophageal eosinophilia is observed during the pollen
season in pollen-sensitized patients (47,48). A likely role for iNKT cells in the process of
allergic sensitization was suggested from studies that showed that food-allergen dependent,
experimental murine EoE could not be induced in CD1d-deficient mice (22). Consistent
with this, we have shown that individual components of the CXCL16–CD1d–iNKT axis are
overexpressed in our entire pediatric EoE population, but increased expression was
significantly more prominent in patients who developed the disease at a very young age.
Epidemiological data from our cohort study further indicate that in patients diagnosed when
< 6 years of age, EoE is characterized by a higher fraction of food-allergic sensitization. In
addition, local mRNA levels of LTC4S, the enzyme that generates the allergic mediator
leukotriene C4, were significantly higher in children with early-onset EoE than in their older
counterparts. As such, these data suggest that this early-onset disease phenotype is likely to
depend more heavily on local sensitization to food-derived allergens. Our results are
therefore supportive of an association between local accumulation of iNKT cells and allergic
sensitization to food antigens in human EoE. Additional support for our concept was
provided recently by Jyonouchi et al., (49) who reported increased numbers of iNKT cells in
esophageal biopsies of pediatric patients with active disease. Upon stimulation with milk-
derived sphingolipids, iNKT cells from these EoE patients readily responded with increased
IL-13 and IL-4, but not interferon-γ production, showing that iNKT cell–mediated responses
to food-derived antigens can be responsible for Th2 skewing of immune responses (49).
Despite recent advances in our understanding of iNKT cell biology, the exact molecular
mechanism that couples iNKT cell infiltration to allergic sensitization in human EoE
patients remains to be further identified. iNKT cells are CD1d-restricted and can be
activated in response to exogenous lipid antigens, including pollen and dust mite–associated
lipids (50,51), as well as dietary antigens such as sphingomyelin derived from milk (52) or
the allergen Ber e1 from Brazil nuts in the presence of a naturally occurring lipid fraction
(53). The study by Olszak et al. (9) has furthermore implicated endogenous (self) antigens
as a source of iNKT stimulation in a pathogenic environmental context and showed that
microbes inhibit this auto-reactivity, at least in part, through dampening CXCL16
expression. It is therefore of interest that we identified a relationship between early-life
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antibiotic use and EoE, suggesting that microbial reduction during early life may also confer
risk for the development of EoE as previously demonstrated for asthma (36,54) and IBD
(35) in humans. Such antibiotic use may diminish the quantity and / or activity of
microorganisms capable of regulating iNKT cells. Interestingly, in this regard is evidence
that Bacteroides fragilis encodes a biosynthetic pathway for the generation of
glycosphingolipids capable of inhibiting colonic iNKT cells, suggesting that antibiotics
which diminish this or similar types of organisms may predispose to iNKT cell-mediated
diseases (55). Our longitudinal cohort study was not designed to specifically address the
potential association between antibiotics use and onset of EoE, which has resulted in
potential under-reporting of early-life antibiotic use and the absence of data on the quantity
or types of antibiotics prescribed. Although our data suggest that the association between
early-life antibiotic exposure and development of EoE was not due to recall bias, we caution
that additional epidemiological studies are needed to prove this important hypothesis. We
propose that EoE is a suitable model disease for such studies, as an association with
antibiotic exposure is less susceptible to reverse causation, which has hampered inference
from pediatric asthmatic cohorts (56). Indeed, gastrointestinal symptoms are less likely to be
treated with antibiotics than upper or lower airway infections, and symptomatology was not
more pronounced in EoE patients compared with controls in our cohort. Supportive of our
data is a recently published paper that has described an association of the same order of
magnitude between EoE and antibiotic use during infancy as found in our study (37). Large
European studies have further pointed out that exposure to a wide variety of environmental
microorganisms confers protection against both atopy and asthma (7), making it reasonable
to surmise that similar mechanisms are operative in EoE.
In summary, we have assessed how recent findings from experimental studies in mouse
models translate to human allergic disease in the context of EoE. Based on our results, we
propose the following model of EoE pathophysiology: (1) Insufficient immune imprinting
by environmental microorganisms results in esophageal upregulation of CXCL16 and
chemotaxis of iNKT cells into the esophagus, making the esophagus susceptible to triggers
of iNKT cell activation; (2) Lipid antigens derived from food, aeroallergens,
microorganisms, and / or potentially self-antigens associated with the esophagus are
inappropriately presented to iNKT cells by CD1d in a manner that stimulates their
pathological activation; (3) Activated iNKT cells serve as an early source of IL-4, IL-5, and
IL-13, facilitating Th2-mediated allergic sensitization and responses that promote and
sustain inflammation. Our observations further suggest that in an esophageal iNKT cell–
dominant disease phenotype, as occurs early in life, allergic inflammation is driven
primarily by food antigens. Conversely, in EoE that manifests at a later age, esophageal
inflammation is potentially less dependent on iNKT cells based upon our findings. This
model of disease pathophysiology suggests that pharmacological interference with CXCL16
and CD1d, especially at a young age and at onset of disease, is a potent target in the
prevention and treatment of allergic diseases such as EoE and may further serve as
diagnostic markers in determining disease etiology and therapeutic response.
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Study Highlights
WHAT IS CURRENT KNOWLEDGE
• The incidence of eosinophilic esophagitis is rapidly increasing.
• Animal studies have demonstrated a role for invariant chain natural killer T
(iNKT) cells in allergic sensitization and susceptibility to allergic immune
disorders.
WHAT IS NEW HERE
• iNKT cells, as well as the cellular components that regulate their chemotaxis
and activation, are increased in esophageal tissue of eosinophilic esophagitis
(EoE) patients.
• Involvement of the iNKT cell pathway is particularly pronounced in patients
with early-onset EoE who have high degrees of sensitization to food antigens.
• Elimination of allergens from diet results in normalization of cellular markers of
the iNKT cell pathway.
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Figure 1.
Components of the C-X-C motif chemokine ligand 16 (CXCL16)–iNKT cell (invariant
chain natural killer T cell)–CD1d pathway are most prominently expressed in early-onset
eosinophilic esophagitis (EoE) patients. Gene expression relative to housekeeping gene
GAPDH (glyceraldehyde 3-phosphate dehydrogenase; expressed as ΔΔ Ct values) is shown
in early-onset EoE patients (< 6 years of age, full circles), EoE patients 6–18 years (open
circles), and non-EoE controls (patients aged < 6 years shown as full squares and patients
aged 6–18 years as open squares) (a–f, h). mRNA expression levels were elevated in EoE
patients compared with non-EoE controls for CXCL16 (a), C-X-C motif chemokine receptor
6 (CXCR6) (b), Vα24 T-cell antigen receptor (TCR) (c), CD3ε (d), and CD1d (f), but not
for CD1a (h). Early-onset EoE patients express significantly higher levels of CXCL16 (a),
CXCR6 (b), and Vα24 TCR (c) when compared with older EoE patients. Ratio of
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expression is plotted for Vα24/CD3ε and Vα24 / CXCR6 (e). (g) Vα24 TCR mRNA levels
correlated significantly with CD1d and CXCL16. Expression values under the detection
limit or the corresponding expression ratios are plotted under the dotted line when
transcripts were not detected. (i) Serum CXCL16 levels of early-onset EoE patients were
compared with age-matched non-EoE controls. (j, k) Serum CXCL16 was correlated to age
at diagnosis. *P < 0.05; **P < 0.01; ***P < 0.001; NS, not significant.
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Figure 2.
C-X-C motif chemokine ligand 16 (CXCL16) correlates with allergic mediators in early-
onset eosinophilic esophagitis (EoE). Early-onset EoE patients do not show (a) more severe
tissue eosinophilia (counts / hpf (high power fields)) or increased expression of EoE-specific
marker genes (c) eotaxin-3, (d) periostin, or (e) interleukin (IL)-13 but show a more
pronounced allergic tissue phenotype as signified by increased expression of (b) leukotriene
C4 synthase (LTC4S). In EoE patients, CXCL16 expression correlates with IL-13 and
disease-specific, IL-13-dependent tissue markers eotaxin-3 (c) and periostin (d). **P < 0.01;
***P < 0.001; NS, not significant.
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Figure 3.
The C-X-C motif chemokine ligand 16 (CXCL16)–iNKT cell (invariant chain natural killer
T cell)–CD1d pathway responds to treatment with dietary elimination of allergens in early-
onset eosinophilic esophagitis (EoE). (a)Tissue eosinophil counts decreased upon successful
treatment (Response +, N = 7) but remained unaltered or increased in non-responders
(Response−, N = 5). (b) CXCL16 mRNA expression levels decreased in all patients upon
treatment but remained significantly elevated in non-responders over responders and
controls. Comparable results were obtained for expression levels of (c) CXCR6 and Vα24
and (d) CD1d. (e) No decrease in CD1a expression was seen upon successful treatment. (f)
Elimination of dietary allergens led to normalization of tissue leukotriene C4 synthase
(LTC4S) mRNA levels in responding but not in non-responding patients. (g) Allergen
avoidance does not affect serum CXCL16 levels in EoE patients. Asterisks represent the
result of statistical testing with Wilcoxon signed rank test for before–after expression levels
and Mann–Whitney U test for post-treatment expression levels as follows: * P < 0.05; * * P
< 0.01; NS, not significant.
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Table 3
Predictors in a cohort-wide logistic regression analysis for a diagnosis of EoE versus non-EoE before
diagnostic endoscopy
Predictor
Univariate analysis Multivariate analysis (N =345)
Odds ratio (95 % CI) P value Odds ratio (95 % CI) P value
Male sex 2.65 (1.77–3.99) < 0.001 2.47 (1.42–4.28) 0.001
Age (per year increase) 1.00 (0.97–1.04) 0.89 1.00 (0.94–1.06) 0.93
Preterm delivery (< 36 weeks) 1.08 (0.69–1.67) 0.73 1.23 (0.67–2.34) 0.51
Hospitalization in the first year of life 0.70 (0.45–1.10) 0.13 0.59 (0.31–1.11) 0.10
Reported asthma 2.35 (1.50–3.69) < 0.001 1.45 (0.80–2.63) 0.22
Reported eczema 2.22 (1.44–3.42) < 0.001 1.60 (0.91–2.79) 0.10
Reported seasonal allergy 4.08 (2.50–6.68) < 0.001 2.90 (1.63–5.18) < 0.001
Any food allergy 5.56 (3.21–9.62) < 0.001 4.58 (2.19–9.57) < 0.001
> 1 annual ear infection requiring antibiotics 1.41 (0.95–2.09) 0.09 1.04 (0.61–1.80) 0.87
Reported antibiotic allergy 1.54 (0.96–2.48) 0.08 1.77 (0.91–3.48) 0.09
Non-antibiotic drugs in the first year of life 0.70 (0.46–1.04) 0.08 0.48 (0.27–0.87) 0.02
Reported antibiotics in the first year of life 4.48 (1.98–10.1) < 0.001 4.10 (1.36–12.35) 0.01
CI, confidence interval; EoE, eosinophilic esophagitis.
Bold values represent statistically significant results.
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